Achieve Life Sciences (ACHV) Share-based Compensation (2010 - 2026)
Achieve Life Sciences (ACHV) recorded quarterly Share-based Compensation of -$685000.0 in Q1 2026, down 152.65% on a QoQ basis from $1.3 million in Q4 2025, and down 130.69% year-over-year from $2.2 million in Q1 2025.
Achieve Life Sciences (ACHV) Share-based Compensation (2010 - 2026) Analysis & Trends
Achieve Life Sciences has disclosed Share-based Compensation across 17 years of filings, most recently posting -$685000.0 for Q1 2026.
- Quarterly Share-based Compensation fell 130.69% year-over-year to -$685000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.8 million (down 6.78% YoY) and the FY2025 annual result came in at $8.8 million, up 64.53% from the prior year.
- Share-based Compensation retreated to -$685000.0 in Q1 2026, from $1.3 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $2.9 million in Q2 2025 and troughed at -$685000.0 in Q1 2026.
- A 5-year average of $1.2 million and a median of $1.2 million in 2023 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2024 — Share-based Compensation jumped 12530.0% — and 2026, when it tumbled 130.69%.
- Tracing ACHV's Share-based Compensation over 5 years: stood at $778000.0 in 2022, then tumbled by 101.29% to -$10000.0 in 2023, then soared by 12530.0% to $1.2 million in 2024, then grew by 4.67% to $1.3 million in 2025, then sank by 152.65% to -$685000.0 in 2026.
- Business Quant data shows ACHV's Share-based Compensation at -$685000.0 in Q1 2026, $1.3 million in Q4 2025, and $2.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 305,000.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 26.47 Mn |
| 10 | Achieve Life Sciences | 93.71 Mn | 63.22 Mn | - | -685,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -685,000.00 |
| Mar 31, 2026 | -685,000.00 |
| Dec 31, 2025 | 1.30 Mn |
| Dec 31, 2025 | 1.30 Mn |
| Sep 30, 2025 | 2.34 Mn |
| Sep 30, 2025 | 2.34 Mn |
| Jun 30, 2025 | 2.89 Mn |
| Jun 30, 2025 | 2.89 Mn |
| Mar 31, 2025 | 2.23 Mn |
| Mar 31, 2025 | 2.23 Mn |
| Dec 31, 2024 | 1.24 Mn |
| Dec 31, 2024 | 1.24 Mn |
| Sep 30, 2024 | 1.34 Mn |
| Sep 30, 2024 | 1.34 Mn |
| Jun 30, 2024 | 1.45 Mn |
| Jun 30, 2024 | 1.45 Mn |
| Mar 31, 2024 | 1.29 Mn |
| Mar 31, 2024 | 1.29 Mn |
| Dec 31, 2023 | -10,000.00 |
| Dec 31, 2023 | -10,000.00 |